Sirenas news
Sirenas, a chemical discovery company harnessing computational metabolomics for “Natural Product” drug discovery, and Hume Supernatural, Inc. (“Hume”), a leading personal care product company, announced today that the companies have entered into a collaboration to bring new natural ingredients from diverse marine and terrestrial sources into the personal care space. The companies plan to work together to identify, test and bring to market ingredients that enhance
Sirenas, LLC ("Sirenas"), a biotechnology company harnessing computational approaches to discover therapeutics derived from the global microbiome, announced today that it has entered into a multi-target research collaboration agreement with Bristol-Myers Squibb to deploy Sirenas` drug discovery platform against certain undisclosed challenging therapeutic targets to identify potential drug candidates. The research collaboration leverages Sirenas` expertise in applying ATLANTIS™, it
Sirenas, LLC ("Sirenas"), a biotechnology company harnessing computational approaches to discover therapeutics derived from nature`s chemistry, announced that it has received a new grant from the Bill & Melinda Gates Foundation to advance ATLANTIS™, the company`s proprietary drug discovery technology. With today`s announcement, Sirenas has now received two research grant awards from the foundation totaling $1.68 M.
ATLANTIS™ u
Sirenas, LLC, a leader in the application of deep data mining approaches to the discovery of new classes of therapeutics from the global microbiome, today announced establishment of their world leading scientific advisory board. This board, with unparalleled expertise in the fields of drug discovery, molecular medicine and medicinal chemistry, includes:
- Benjamin Cravatt, Ph.D., professor and co-chair of the Department of Molecular Medicine at The
When Eduardo Esquenazi was 28, he abruptly went from being a semiprofessional surfer and UC San Diego doctoral student to a patient at Memorial Sloan Kettering Cancer Center in New York.
Diagnosed with testicular cancer, Esquenazi put his neurobiology studies on hold to embark on an intense treatment plan that included multiple rounds of chemotherapy. It turned his world upside down, but it saved his life—and also gave him the idea for an unusual biotechnology